Related Experiment Video
Updated: May 2, 2026

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019
Malignant mesothelioma
Ishtiaq Ahmed1, Salman Ahmed Tipu2, Sundas Ishtiaq3
1Prof. Dr. Ishtiaq Ahmed, Professor, Department of Surgery, Al-Nafees Medical College, Islamabad, Pakistan.
Unlabelled:
Malignant Mesothelioma (MM) is a rare but rapidly fatal and aggressive tumor of the pleura and peritoneum with limited knowledge of its natural history. The incidence has increased in the past two decades but still it is a rare tumor. Etiology of all forms of mesothelioma is strongly associated with industrial pollutants, of which asbestos is the principal carcinogen. Mesothelioma is an insidious neoplasm arising from mesothelial surfaces i.e., pleura (65%-70%), peritoneum (30%), tunica vaginalis testis, and pericardium (1%-2%). The diagnosis of peritoneal and Pleural mesothelioma is often delayed, due to a long latent period between onset and symptoms and the common and nonspecific clinical presentation. The definite diagnosis can only be established by diagnostic laparoscopy or open surgery along with biopsy to obtain histological examination and immunocytochemical analysis. Different treatment options are available but Surgery can achieve a complete or incomplete resection and Radical resection is the preferred treatment. Chemotherapy has an important role in palliative treatment. Photodynamic therapy is also an option under trial. Patients who successfully underwent surgical resection had a considerably longer median survival as well as a significantly higher 5-year survival. Source of Data/Study Selection: The data were collected from case reports, cross-sectional studies, Open-label studies and phase -II trials between 1973-2012.
Data Extraction:
Web sites and other online resources of American college of surgeons, Medline, NCBI and Medscape resource centers were used to extract data.
Conclusion:
Malignant Mesothelioma (MM) is a rare but rapidly fatal and aggressive tumor with limited knowledge of its natural history. The diagnosis of peritoneal and Pleural mesothelioma is often delayed, so level of index of suspicion must be kept high.
Insights
Malignant mesothelioma (MM) is a rare, aggressive cancer linked to asbestos exposure. Early diagnosis is crucial, as surgical resection offers the best survival outcomes for this challenging disease.
Area of Science:
- Oncology
- Pathology
Background:
- Malignant Mesothelioma (MM) is a rare, aggressive neoplasm affecting mesothelial surfaces like the pleura and peritoneum.
- Its etiology is strongly linked to asbestos exposure, a principal carcinogen from industrial pollutants.
- The natural history of MM is not well understood, contributing to diagnostic delays.
Purpose of the Study:
- To review the etiology, diagnosis, and treatment of Malignant Mesothelioma.
- To highlight the importance of early detection and the role of surgery in improving patient survival.
Main Methods:
- Data were collected from case reports, cross-sectional studies, open-label studies, and phase-II trials.
- Literature search conducted using online resources from the American College of Surgeons, Medline, NCBI, and Medscape.
Main Results:
- Malignant Mesothelioma (MM) is a rare but aggressive tumor with increased incidence.
- Diagnosis is often delayed due to long latent periods and nonspecific symptoms.
- Radical surgical resection is the preferred treatment, significantly improving median and 5-year survival rates.
Conclusions:
- Malignant Mesothelioma (MM) remains a rare, aggressive, and often fatal tumor.
- A high index of suspicion is necessary for timely diagnosis due to frequent delays.
- Surgical intervention offers the most promising survival benefit for patients with MM.
Related Concept Videos
Pleural Disorders: Types and Brief Description
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

